Amarin Corp Plc (AMRN)

[sts66]

Amarin has specific patents related to non active ingredients in capsule preserving the active form. The "generic" document DEMANDS the same inactive ingredients thus validating the Patent until 2030

Thanks for the clarification.....when I read that doc yesterday I was puzzled by the "identical inactive ingredient" clause, as for most drugs in pill for the IAI are fillers for the most part and have no effect on the drug activity....but in this case, it appears that the IAI play a part in keeping the EPA in a stable form over time, which AMRN has patented? That's huge if I got that right - no generic competition until 2030 unless the patents don't hold up in court, and I can't see how they won't.